Witek Natalie, Comella Cynthia
Rush University Medical Center, Section of Movement Disorders, Rush Parkinson's Disease & Movement Disorders Program, 1725 W Harrison St., Suite 755, Chicago, IL 60612, USA.
Neurodegener Dis Manag. 2019 Apr;9(2):73-81. doi: 10.2217/nmt-2019-0001. Epub 2019 Feb 6.
Tardive dyskinesia (TD) is a bothersome and - at times, disabling - movement disorder associated with exposure to dopamine receptor antagonist medications. On 11 April 2017, valbenazine became the first US FDA-approved medication indicated for the treatment of TD. Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor that decreases the abnormal movements of TD. The FDA considered valbenazine a breakthrough therapy in 2014 given its underlying mechanism and its importance in addressing an unmet need, as there were no available FDA-approved medications indicated for TD. The advantages of valbenazine include once-daily dosing and a rapid onset of effect within 2 weeks of treatment initiation.
迟发性运动障碍（TD）是一种令人烦恼且有时会导致残疾的运动障碍，与接触多巴胺受体拮抗剂药物有关。2017年4月11日，氘代丁苯那嗪成为美国食品药品监督管理局（FDA）批准的首个用于治疗TD的药物。氘代丁苯那嗪是一种囊泡单胺转运体2（VMAT2）抑制剂，可减少TD的异常运动。鉴于其潜在机制及其在满足未被满足的需求方面的重要性，FDA在2014年将氘代丁苯那嗪视为一种突破性疗法，因为当时尚无FDA批准的用于TD的药物。氘代丁苯那嗪的优点包括每日一次给药以及在开始治疗后2周内迅速起效。
